JNJ vs XOM: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Exxon Mobil Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
Exxon Mobil Corporation · Energy
$163.18
+10.3% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
XOM has more upside to fair value
(+10.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
XOM |
| Current Price |
$270.68 |
$163.18 |
| Fair Value Estimate |
$286.05 |
$179.98 |
| Upside to Fair Value |
+5.7%
|
+10.3%
|
| Market Cap |
$652.3B |
$676.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
20.2x
|
9.9x
|
| Price / Sales |
6.7x
|
1.9x
|
| Price / FCF |
35.3x
|
22.3x
|
| Revenue Growth YoY |
+6.6%
|
+44.1%
|
| Gross Margin |
67.9%
|
25.1%
|
| Operating Margin |
26.8%
|
10.7%
|
| Return on Equity |
25.7%
|
12.7%
|
| Dividend Yield |
1.95% |
2.52% |
| FCF Yield |
2.83%
|
4.49%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Exxon Mobil is the largest integrated oil and gas major in the United States, operating across Upstream exploration and production, Downstream refining and fuels marketing, and Chemical manufacturing, with roughly 57,900 employees and a portfolio that spans conventional crude and natural gas, LNG, petrochemicals, and early-stage carbon capture, hydrogen, and biofuels ventures. The business qualit…
Accumulation Zones
| Metric |
JNJ |
XOM |
| Zone Low |
$214.54 |
$134.98 |
| Zone High |
$243.14 |
$152.98 |
| In Buy Zone? |
No
|
No
|